This Mayo Clinic study followed 2,000 consecutive primary Charnley cemented total hip arthroplasties (1,689 patients, performed 1969–1971) for 25 years. It used Kaplan-Meier analysis to determine how patient age, sex, and diagnosis independently affect acetabular and femoral component survivorship. The cohort is large enough to provide statistically valid comparisons across demographic subgroups — something prior series could not do.
The single most important number in this paper is the age-stratified survivorship table. When a 38-year-old with hip OA asks how long a replacement will last, you can say: roughly 1 in 3 patients under 40 will need revision by 25 years — and that was with first-generation cementing technique where revision risk was likely higher than modern methods.
When counseling patients, three rules follow directly from this data. First, the younger the patient, the more aggressively you should explore joint-preserving alternatives before committing to arthroplasty. Second, male patients need to understand they carry roughly twice the revision risk of female patients. This is not a small difference. Third, DDH as the indication should prompt a specific conversation about the acetabular side: it carries a 2.1-fold higher odds of cup loosening, and overall 25-year survivorship in this group was only 65.9%.
The temporal pattern of failure is also clinically useful: if you are seeing a patient 10 years out from cemented THA with femoral symptoms, that tracks with the known early predominance of femoral loosening. A patient presenting 20+ years out with new groin pain should raise concern for late acetabular loosening, which this paper shows accelerates after 15 years.
This Mayo Clinic study followed 2,000 consecutive primary Charnley cemented total hip arthroplasties (1,689 patients, performed 1969–1971) for 25 years. It used Kaplan-Meier analysis to determine how patient age, sex, and diagnosis independently affect acetabular and femoral component survivorship. The cohort is large enough to provide statistically valid comparisons across demographic subgroups — something prior series could not do.
The single most important number in this paper is the age-stratified survivorship table. When a 38-year-old with hip OA asks how long a replacement will last, you can say: roughly 1 in 3 patients under 40 will need revision by 25 years — and that was with first-generation cementing technique where revision risk was likely higher than modern methods.
When counseling patients, three rules follow directly from this data. First, the younger the patient, the more aggressively you should explore joint-preserving alternatives before committing to arthroplasty. Second, male patients need to understand they carry roughly twice the revision risk of female patients. This is not a small difference. Third, DDH as the indication should prompt a specific conversation about the acetabular side: it carries a 2.1-fold higher odds of cup loosening, and overall 25-year survivorship in this group was only 65.9%.
The temporal pattern of failure is also clinically useful: if you are seeing a patient 10 years out from cemented THA with femoral symptoms, that tracks with the known early predominance of femoral loosening. A patient presenting 20+ years out with new groin pain should raise concern for late acetabular loosening, which this paper shows accelerates after 15 years.